Du är här

2016-02-25

CORRECTION: Targovax ASA: Invitation to Fourth Quarter 2015 Results Presentation

This is a correction of the announcement from 08:00 25.02.2016 CET.
Targovax ASA (Targovax) will release its Q4 2015 results on Wednesday 2 March
2016 at 07:00 CET. The quarterly report and the presentation material will be
available at this time atwww.targovax.com.

A presentation of the results will be held at 09:30 CET at Hotel Continental
Conference Center, Stortingsgaten 24/26, Oslo, Norway.

CEO Gunnar Gårdemyr, CFO Øystein Soug and CMO Magnus Jäderberg will be
representing the company.

At 14:00 CET (08:00 EST) the same day, Targovax will host a telephone
conference, including a presentation of the results, following with a Q&A
session. Call in details below.

Please make sure to dial in at least 5-10 minutes ahead of time to complete
your registration.

Participant information:

Call in numbers:

Norway Toll-Free Number: 800 19 747
Norway Toll Number: +472350 0559
UK Toll-Free Number: 08082370030
UK Toll Number: +442031394830
US Toll-Free Number: 1866 928 7517
US Toll Number: +1 718 873 9077

See attached list for more dial in numbers.
http://wpc.1726.planetstream.net/001726/FEL_Events_International_Access_...

Access code:

16490430#

For further information, please contact:

Gunnar Gårdemyr
CEO
Phone: +41 798 340 585
Email:ggardemyr@targovax.com

Øystein Soug
CFO
Phone: +47 906 56 525
Email:oystein.soug@targovax.com

Elisabeth Haugen Barter
PR Coordinator
Phone: +47 900 61 664
Email:elisabeth.barter@targovax.com

About Targovax:
"Arming patient's immune system to fight cancer"

Targovax is a clinical stage immuno-oncology company developing targeted
immunotherapy treatments for cancer patients. Targovax has a broad and
diversified immune therapy portfolio and aim to become a leader in its area.
The company is currently developing two complementary and highly targeted
approaches in immuno-oncology:

Oncos 102
is a virus-based immunotherapy platform based on engineered oncolytic viruses
armed with potent immune-stimulating transgenes targeting solid tumors. This
treatment may reinstate the immune system's capacity to recognize and attack
cancer cells.

TG01 and TG02
are part of a peptide-based immunotherapy platform targeting the difficult to
treat RAS mutations found in more than 85% of pancreatic cancers, 50% of
colorectal cancer and 20-30% of all cancers. Targovax works towards
demonstrating that TG vaccines will prolong time to cancer progression and
increase survival.

The product candidates will be developed in combination with multiple
treatments in several cancer indications, including checkpoint inhibitors.
Targovax also has a number of other cancer immune therapy candidates in the
early stage of development. For more information go towww.targovax.com.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Targovax ASA via Globenewswire

HUG#1989273

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.